News
ANIK
12.92
-3.58%
-0.48
Anika Therapeutics Price Target Cut to $17.00/Share From $23.00 by B. Riley Securities
Dow Jones · 11h ago
B. Riley Securities Reiterates Buy on Anika Therapeutics, Lowers Price Target to $17
Benzinga · 11h ago
Anika Therapeutics price target raised to $23 from $17 at B. Riley
TipRanks · 11h ago
Weekly Report: what happened at ANIK last week (1109-1113)?
Weekly Report · 15h ago
Analysts Are Bullish on Top Healthcare Stocks: Aquestive Therapeutics (AQST), Kardigan, Inc. (KARD)
TipRanks · 11/09 12:50
Weekly Report: what happened at ANIK last week (1102-1106)?
Weekly Report · 11/09 09:41
Anika Therapeutics Q3 Revenue Rises 10%; Raises 2026 Outlook
NASDAQ · 11/09 07:25
Anika Therapeutics Reports Third Quarter 2026 Revenue of $30.6 million
NASDAQ · 11/06 17:19
Anika Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 11/06 14:13
Anika Therapeutics reports Q3 adjusted EPS 29c, consensus 17c
TipRanks · 11/06 12:28
Anika Therapeutics narrows FY26 revenue view to up 6%-10% from up 5%-10%
TipRanks · 11/06 12:27
Anika Therapeutics backs FY27 revenue view flat to up 5%
TipRanks · 11/06 12:27
Anika Therapeutics GAAP EPS of -$0.02 misses by $0.08, revenue of $30.59M beats by $1.15M
Seeking Alpha · 11/06 12:13
Anika Therapeutics Raises FY2026 Sales Guidance from $118.460M-$124.101M to $119.588M-$124.101M vs $121.639M Est
Benzinga · 11/06 12:06
*Anika Therapeutics Raises Lower End of Full-Year Total Rev Guidance
Dow Jones · 11/06 12:06
*Anika Therapeutics 3Q Rev $30.6M >ANIK
Dow Jones · 11/06 12:05
*Anika Therapeutics 3Q Loss/Shr 2c >ANIK
Dow Jones · 11/06 12:05
*Anika Therapeutics 3Q Adj EPS 29c >ANIK
Dow Jones · 11/06 12:05
Press Release: Anika Reports Third Quarter 2026 Financial Results
Dow Jones · 11/06 12:05
*Anika Therapeutics 3Q Loss $311,000 >ANIK
Dow Jones · 11/06 12:05
More
Webull provides a variety of real-time ANIK stock news. You can receive the latest news about Anika Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANIK
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.